Henry Schein, Inc. (NASDAQ:HSIC) – Equities research analysts at Barrington Research upped their Q4 2017 earnings per share (EPS) estimates for Henry Schein in a report released on Tuesday. Barrington Research analyst M. Petusky now forecasts that the company will post earnings of $1.00 per share for the quarter, up from their prior forecast of $1.00. Barrington Research also issued estimates for Henry Schein’s Q1 2018 earnings at $0.94 EPS.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.86 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The company had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the company posted $0.82 EPS. Henry Schein’s quarterly revenue was up 6.4% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/26/barrington-research-comments-on-henry-schein-inc-s-q4-2017-earnings-hsic.html.

Other equities analysts also recently issued research reports about the company. UBS Group AG restated a “buy” rating on shares of Henry Schein in a research report on Friday, September 15th. Northcoast Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 target price for the company in a research note on Monday, August 7th. Robert W. Baird set a $95.00 target price on Henry Schein and gave the company a “buy” rating in a research note on Thursday, October 19th. Morgan Stanley assumed coverage on Henry Schein in a research note on Thursday, September 21st. They issued an “equal weight” rating and a $88.00 target price for the company. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $89.00 target price on shares of Henry Schein in a research note on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and six have issued a buy rating to the stock. Henry Schein presently has a consensus rating of “Hold” and an average target price of $92.89.

Shares of Henry Schein (NASDAQ HSIC) traded up 0.43% during midday trading on Thursday, hitting $83.26. The stock had a trading volume of 118,078 shares. The firm has a market cap of $13.16 billion, a PE ratio of 24.33 and a beta of 1.08. Henry Schein has a 12-month low of $73.11 and a 12-month high of $93.50. The firm has a 50-day moving average of $82.28 and a 200 day moving average of $87.26.

Henry Schein declared that its board has approved a stock buyback program on Monday, September 18th that permits the company to buyback $400.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 6.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

In other Henry Schein news, SVP Paul Rose sold 2,126 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the sale, the senior vice president now directly owns 17,841 shares in the company, valued at approximately $3,077,750.91. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.19% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Intrust Bank NA lifted its position in Henry Schein by 1.1% in the 2nd quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock valued at $223,000 after acquiring an additional 13 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its position in shares of Henry Schein by 4.0% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 14,859 shares of the company’s stock worth $2,719,000 after buying an additional 566 shares in the last quarter. Bradley Foster & Sargent Inc. CT lifted its position in shares of Henry Schein by 2.1% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 33,106 shares of the company’s stock worth $6,059,000 after buying an additional 690 shares in the last quarter. Comerica Bank lifted its position in shares of Henry Schein by 10.6% during the 2nd quarter. Comerica Bank now owns 21,833 shares of the company’s stock worth $4,054,000 after buying an additional 2,101 shares in the last quarter. Finally, Aviva PLC lifted its position in shares of Henry Schein by 0.5% during the 2nd quarter. Aviva PLC now owns 50,249 shares of the company’s stock worth $9,195,000 after buying an additional 230 shares in the last quarter. 45.90% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.